Detection of impaired renal function: Is the modern serologic marker cystatin C more accurate than the 99mTc-MAG3 clearance?;Nachweis der eingeschränkten nierenfunktion: Ist der moderne serologische marker cystatin C der 99mTc-MAG3-clearance überlegen?

NuklearMedizin

Volumn 43, Issue 6, 2004, Pages 203-209

  Reinhardt, Michael J ^a   Weidling, H ^a   Breuel, H P ^a   Biersack, H J ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

99mTc MAG3 clearance; Creatinine clearance; Cystatin C

Indexed keywords

CREATININE; CYSTATIN C; MERTIATIDE TC 99M;

ADULT; AGED; ARTICLE; CAUCASIAN; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DRUG CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE;

EID: 11144317916     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623917     Document Type: Article

References (33)

1. American Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care 2001; 24 (Suppl): 33-43.
2. Anonymous. Excerpts from the 2000 U.S. renal data system annual data report: atlas of end stage renal disease in the United States. Am J Kidney Dis 2000; 36 (Suppl. 1): S1-279.
3. Bubeck B, Brandau W, Weber E et al. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med 1990; 31: 1285-93.
4. Bubeck B, Piepenburg R, Grethe U et al. A new principle to normalize plasma concentrations allowing single-sample clearance determinations in both children and adults. Eur J Nucl Med 1992; 19: 511-6.
5. Bubeck B. Renal clearance determination with one blood sample: improved accuracy and universal applicability by a new calculation principle. Sem Nucl Med 1993; 23: 73-86.
6. Buysschaert M, Joudi I, Wallemacq P et al. Comparative performance of serum cystatin-C versus serum creatinine in diabetic subjects. Diabetes Metab 2003; 29: 377-83.
7. Christensson A, Ekberg J, Grubb A et al. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. Nephron Physiol 2003; 94: 19-27.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
9. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
10. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-16.
11. Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens 2003; 5 (Suppl 2), 14-22.
12. Harmoinen A, Lehtimaki T, Korpela M et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 2003; 49: 1223-5.
13. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-7
14. Herget-Rosenthal S, Trabold S, Pietruck F et al. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20: 97-102.
15. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-31.
16. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707.
17. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
18. Levey AS, Coresh J, Balk E et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
19. Mailloux L, Gagnon JA. Measurement of effective renal plasma flow. Progr Nucl Med 1972; 2: 54-70.
20. McClellan WM, Knight DF, Karp H et al. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 1997; 29: 368-75.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1): S1-266.
22. Newman DJ. Cystatin C. Ann Clin Biochem 2002; 39: 89-104.
23. Perlemoine C, Beauvieux MC, Rigalleau V et al. Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism: Clin Experiment 2003; 52: 1258-64.
24. Poge U, Stoschus B, Stoffel-Wagner B et al. Cystatin C as an endogenous marker of glomerular filtration rate in renal transplant patients. Kidney Blood Press Res 2003; 26: 55-60.
25. 3 clearance - is there a difference in clinical routine? Eur J Nucl Med 2003; 30 (Suppl 2): S368.
26. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136: 604-15.
27. 3 plasma clearance in adults from one or two blood samples. J Nucl Med 1989; 30: 1955-9.
28. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
29. Smith HW. Comparative physiology of the kidney. In: Smith HW (ed). The kidney: structure and function in health and disease. New York, Oxford: University Press 1951; 520-74.
30. Tauxe WN, Maher FT, Taylor WF. Effective renal plasma flow: estimation from theoretical volumes of distribution of intravenously injected 131-I orthoiodo-hippurate. Mayo Clin Proc 1971; 46: 524-31.
31. Taylor A. Radionuclide renography: a personal approach. Sem Nucl Med 1999; 29: 102-27.
32. Wenzel U, Dominiak P, Neumayer HH et al. Hemmung der Progression von chronischen Nierenerkrankungen. Deutsches Ärzteblatt 2003; 100: 2072-9.
33. Wu PS, Chiu NT, Lee BF et al. Relationship of formula creatinine clearance, serum creatinine and blood urea nitrogen to 99mTc-MAG3 Clearance. Ann Nucl Med Sci 2002; 15: 77-83.